The abstract is read at the publisher; the summary is JClub's.
Biased agonism in GPCR pharmacology is now established as the rule, with structural insights showing agonists stabilize distinct agonist:GPCR ensembles that differentially activate downstream pathways.
- Why it matters: The field lagged because earlier tools could not monitor multiple transducers and signaling routes, and because tested agonists lacked chemical diversity, limiting recognition of pathway selectivity.
- What they did: The review synthesizes pharmacological, mechanistic, and structural evidence, emphasizing how new agonist:receptor:transducer structures enable tracking of distinct transducer coupling and binding modes.
- The result: By leveraging this structural basis, biased agonism is positioned to reshape drug discovery toward more precise therapeutics with optimized pharmacological profiles that selectively target signaling pathways downstream of receptors.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.